Nadim Mahmud1, David E Kaplan1,2, Tamar H Taddei3,4, David S Goldberg1,5. 1. Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 2. Department of Medicine, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA. 3. Division of Digestive Diseases, School of Medicine, Yale University, New Haven, CT. 4. Veterans Affairs Connecticut Healthcare System, West Haven, CT. 5. Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Abstract
The term acute-on-chronic liver failure (ACLF) is intended to identify patients with chronic liver disease who develop rapid deterioration of liver function and high short-term mortality after an acute insult. The two prominent definitions (European Association for the Study of the Liver [EASL] and Asian Pacific Association for the Study of the Liver [APASL]) differ, and existing literature applies to narrow patient groups. We sought to compare ACLF incidence and mortality among a diverse cohort of patients with compensated cirrhosis, using both definitions. This was a retrospective cohort study of patients with incident compensated cirrhosis in the Veterans Health Administration from 2008 to 2016. First ACLF events were identified for each definition. Incidence rates were computed as events per 1,000 person-years, and mortality was calculated at 28 and 90 days. Among 80,383 patients with cirrhosis with 3.35 years median follow-up, 783 developed EASL and APASL ACLF, 4,296 developed EASL ACLF alone, and 574 developed APASL ACLF alone. The incidence rate of APASL ACLF was 5.7 per 1,000 person-years (95% confidence interval [CI]: 5.4-6.0), and the incidence rate of EASL ACLF was 20.1 (95% CI: 19.5-20.6). The 28-day and 90-day mortalities for APASL ACLF were 41.9% and 56.1%, respectively, and were 37.6% and 50.4% for EASL ACLF. The median bilirubin level at diagnosis of EASL-alone ACLF was 2.0 mg/dL (interquartile range: 1.1-4.0). Patients with hepatitis C or nonalcoholic fatty liver disease had among the lowest ACLF incidence rates but had the highest short-term mortality. Conclusion: There is significant discordance in ACLF events by EASL and APASL criteria. The majority of patients with EASL-alone ACLF have preserved liver function, suggesting the need for more liver-specific ACLF criteria.
The term acute-on-chronic liver failure (ACLF) is intended to identify patients with chronic liver disease who develop rapid deterioration of liver function and high short-term mortality after an acute insult. The two prominent definitions (European Association for the Study of the Liver [EASL] and Asian Pacific Association for the Study of the Liver [APASL]) differ, and existing literature applies to narrow patient groups. We sought to compare ACLF incidence and mortality among a diverse cohort of patients with compensated cirrhosis, using both definitions. This was a retrospective cohort study of patients with incident compensated cirrhosis in the Veterans Health Administration from 2008 to 2016. First ACLF events were identified for each definition. Incidence rates were computed as events per 1,000 person-years, and mortality was calculated at 28 and 90 days. Among 80,383 patients with cirrhosis with 3.35 years median follow-up, 783 developed EASL and APASL ACLF, 4,296 developed EASL ACLF alone, and 574 developed APASL ACLF alone. The incidence rate of APASL ACLF was 5.7 per 1,000 person-years (95% confidence interval [CI]: 5.4-6.0), and the incidence rate of EASL ACLF was 20.1 (95% CI: 19.5-20.6). The 28-day and 90-day mortalities for APASL ACLF were 41.9% and 56.1%, respectively, and were 37.6% and 50.4% for EASL ACLF. The median bilirubin level at diagnosis of EASL-alone ACLF was 2.0 mg/dL (interquartile range: 1.1-4.0). Patients with hepatitis C or nonalcoholic fatty liver disease had among the lowest ACLF incidence rates but had the highest short-term mortality. Conclusion: There is significant discordance in ACLF events by EASL and APASL criteria. The majority of patients with EASL-alone ACLF have preserved liver function, suggesting the need for more liver-specific ACLF criteria.
Authors: Philippe Mathurin; Charles L Mendenhall; Robert L Carithers; Marie-Jose Ramond; Willis C Maddrey; Peter Garstide; Bernard Rueff; Sylvie Naveau; Jean-Claude Chaput; Thierry Poynard Journal: J Hepatol Date: 2002-04 Impact factor: 25.083
Authors: Sebastian Schneeweiss; Ari Robicsek; Richard Scranton; Dan Zuckerman; Daniel H Solomon Journal: J Clin Epidemiol Date: 2006-12-18 Impact factor: 6.437
Authors: Peter M Wahl; Keith Rodgers; Sebastian Schneeweiss; Brian F Gage; Javed Butler; Charles Wilmer; Marshall Nash; Gregory Esper; Norman Gitlin; Neal Osborn; Louise J Short; Rhonda L Bohn Journal: Pharmacoepidemiol Drug Saf Date: 2010-06 Impact factor: 2.890
Authors: Vincent Lo Re; Joseph K Lim; Matthew Bidwell Goetz; Janet Tate; Harini Bathulapalli; Marina B Klein; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Cynthia L Gibert; Sheldon T Brown; Farah Kidwai; Cynthia Brandt; Zachariah Dorey-Stein; K Rajender Reddy; Amy C Justice Journal: Pharmacoepidemiol Drug Saf Date: 2011-05-27 Impact factor: 2.890
Authors: B W Gillespie; R M Merion; E Ortiz-Rios; L Tong; A Shaked; R S Brown; A O Ojo; P H Hayashi; C L Berg; M M Abecassis; A S Ashworth; C E Friese; J C Hong; J F Trotter; J E Everhart Journal: Am J Transplant Date: 2010-02-25 Impact factor: 8.086
Authors: Philippe Mathurin; John O'Grady; Robert L Carithers; Martin Phillips; Alexandre Louvet; Charles L Mendenhall; Marie-José Ramond; Sylvie Naveau; Willis C Maddrey; Timothy R Morgan Journal: Gut Date: 2010-10-12 Impact factor: 23.059
Authors: Karen Y Xiao; Rebecca A Hubbard; David E Kaplan; Tamar H Taddei; David S Goldberg; Nadim Mahmud Journal: Hepatol Int Date: 2020-06-09 Impact factor: 6.047
Authors: Nadim Mahmud; Sumeet K Asrani; David E Kaplan; Gerald O Ogola; Tamar H Taddei; Patrick S Kamath; Marina Serper Journal: Liver Transpl Date: 2020-12-09 Impact factor: 5.799